The Human Phospholipase B-II Precursor (HPLBII-P) in Urine As a Novel Biomarker of Glomerular Activity in COVID-19 and Diabetes Mellitus

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 May 11

PMID 38731071

Authors

Shengyuan Xu

Michael Hultstrom

Anders Larsson

Miklos Lipcsey

Cecilia Lindskog

Sara Bulow

Robert Frithiof

Per Venge

Affiliations

Soon will be listed here.

Abstract

The human phospholipase B-II precursor (HPLBII-P) was originally purified from white blood cells but is also found in other cellular structures, such as kidney glomeruli and tubuli. The objective of this report was to investigate the relationship of HPLBII-P in urine to acute kidney injury in patients with COVID-19. Urine was collected at admission from 132 patients with COVID-19 admitted to the intensive care units (ICUs) because of respiratory failure. HPLBII-P was measured using a sensitive ELISA. For comparison, human neutrophil lipocalin (HNL) was measured in urine, using the ELISA configured with the monoclonal antibody 763/8F, as a sign of tubular affection in addition to routine biomarkers of kidney disease. Overall, the concentrations of urinary HPLBII-P were almost 3-fold higher in patients with COVID-19 compared to healthy controls ( < 0.0001) and with significantly higher concentrations even in patients with COVID-19 without signs of acute kidney injury (AKI) ( < 0.001). HPLBII-P was further increased in patients with AKI ( < 0.02). HPLBII-P was significantly increased in patients with diabetes mellitus ( = 0.0008) and correlated to plasma glucose (r = 0.29, = 0.001) and urine albumin concentrations (r = 0.55, < 0.001). Urine concentrations of HPLBII-P are highly raised in the urine of patients with COVID-19 and relate to AKI and diabetes mellitus. HPLBII-P may reflect glomerular injury and/or increased glomerular cell activity in SARS-CoV-2 infections.

References

Jana S, Mitra P, Roy S . Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review. Diseases. 2023; 11(1). PMC: 9844481. DOI: 10.3390/diseases11010008. View

Nguyen M, Devarajan P . Biomarkers for the early detection of acute kidney injury. Pediatr Nephrol. 2007; 23(12):2151-7. PMC: 6904376. DOI: 10.1007/s00467-007-0470-x. View

Kjeldsen L, Sengelov H, Lollike K, Nielsen M, Borregaard N . Isolation and characterization of gelatinase granules from human neutrophils. Blood. 1994; 83(6):1640-9. View

Ripon M, Bhowmik D, Amin M, Hossain M . Role of arachidonic cascade in COVID-19 infection: A review. Prostaglandins Other Lipid Mediat. 2021; 154:106539. PMC: 7882227. DOI: 10.1016/j.prostaglandins.2021.106539. View

Kandasamy Y, Smith R, Lumbers E, Rudd D . Nephrin - a biomarker of early glomerular injury. Biomark Res. 2015; 2:21. PMC: 4363192. DOI: 10.1186/2050-7771-2-21. View

Khwaja A . KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012; 120(4):c179-84. DOI: 10.1159/000339789. View

Weil E, Lemley K, Yee B, Lovato T, Richardson M, Myers B . Podocyte detachment in type 2 diabetic nephropathy. Am J Nephrol. 2011; 33 Suppl 1:21-4. PMC: 3121550. DOI: 10.1159/000327047. View

Grubb A . Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol. 1992; 38 Suppl 1:S20-7. View

Frithiof R, Bergqvist A, Jarhult J, Lipcsey M, Hultstrom M . Presence of SARS-CoV-2 in urine is rare and not associated with acute kidney injury in critically ill COVID-19 patients. Crit Care. 2020; 24(1):587. PMC: 7523248. DOI: 10.1186/s13054-020-03302-w. View

10.

Luther T, Bulow-Anderberg S, Larsson A, Rubertsson S, Lipcsey M, Frithiof R . COVID-19 patients in intensive care develop predominantly oliguric acute kidney injury. Acta Anaesthesiol Scand. 2020; 65(3):364-372. PMC: 7753792. DOI: 10.1111/aas.13746. View

11.

Xu S, Carlson M, Engstrom A, Garcia R, PETERSON C, Venge P . Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scand J Clin Lab Invest. 1994; 54(5):365-76. DOI: 10.3109/00365519409088436. View

12.

Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw S, Bell M . Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013; 17(1):R25. PMC: 4057242. DOI: 10.1186/cc12503. View

13.

Teixeira S, Borges B, Oliveira V, Carregosa L, Bastos L, Santos I . Insights into the antiviral activity of phospholipases A (PLAs) from snake venoms. Int J Biol Macromol. 2020; 164:616-625. PMC: 7368918. DOI: 10.1016/j.ijbiomac.2020.07.178. View

14.

Shetty A, Tawhari I, Safar-Boueri L, Seif N, Alahmadi A, Gargiulo R . COVID-19-Associated Glomerular Disease. J Am Soc Nephrol. 2020; 32(1):33-40. PMC: 7894674. DOI: 10.1681/ASN.2020060804. View

15.

Xu S, Cai L, Zhao L, Douhan-Hakansson L, Kristjansson G, Pauksen K . Tissue localization and the establishment of a sensitive immunoassay of the newly discovered human phospholipase B-precursor (PLB-P). J Immunol Methods. 2010; 353(1-2):71-7. DOI: 10.1016/j.jim.2010.01.005. View

16.

Abbate M, Rottoli D, Gianatti A . COVID-19 Attacks the Kidney: Ultrastructural Evidence for the Presence of Virus in the Glomerular Epithelium. Nephron. 2020; 144(7):341-342. PMC: 7316662. DOI: 10.1159/000508430. View

17.

Pagtalunan M, Miller P, Nelson R, Myers B, Rennke H, COPLON N . Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997; 99(2):342-8. PMC: 507802. DOI: 10.1172/JCI119163. View

18.

Xu S, Zhao L, Larsson A, Venge P . The identification of a phospholipase B precursor in human neutrophils. FEBS J. 2008; 276(1):175-86. DOI: 10.1111/j.1742-4658.2008.06771.x. View

19.

Zylka A, Dumnicka P, Kusnierz-Cabala B, Gala-Bladzinska A, Ceranowicz P, Kucharz J . Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients. Mediators Inflamm. 2018; 2018:7659243. PMC: 6109534. DOI: 10.1155/2018/7659243. View

20.

Giasson J, Li G, Chen Y . Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non--acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets. 2011; 10(4):272-82. DOI: 10.2174/187152811796117753. View